Tradestie Institutional Equity Comparison Engine

NVS vs ABBV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABBV Overall Edge

ABBV Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abbvie Inc. (ABBV) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NVS counters with relative strength in Valuation. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus ABBV at 18.2x Forward P/E and 36.6% operating margin (+10.3% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against ABBV sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NVS
NVS 16.2x vs ABBV 18.2x Fwd P/E
Growth & Margin Winner ABBV
Op Margin 34.0% vs 36.6% ยท YoY +4.7% vs +10.3%
Momentum & Technical Winner ABBV
1Y +22.5% vs +27.4% ยท 52W Pos 81% vs 94%
Options & Structure Winner ABBV
UNCLASSIFIED (6th %ile IV) vs BREAKOUT (12th %ile IV)
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
1M Return +7.28%
1Y Return +22.5%
Forward P/E 16.2x
Unified AI Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
ABBV NYSE
Abbvie Inc.
Pharmaceutical Preparations
$295.94
+0.31% 1D
Market Cap $520.5B
1M Return +3.69%
1Y Return +27.4%
Forward P/E 18.2x
Unified AI Score
54.0 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 72.0 Mom 46.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVS +22.5% ABBV +27.4% Spread: +4.9 pp (ABBV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVS TTM Op. Margin: 34.0% ABBV TTM Op. Margin: 36.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs ABBV. Trailing 12-month operating profitability (NVS 34.0% vs ABBV 36.6%) and valuation multiples (NVS 16.2x vs ABBV 18.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVS (3) vs ABBV (7)
Institutional Metric NVS ABBV Criterion Row Winner
Market Capitalization Scale $302.9B $520.5B Larger Scale ABBV
Trailing P/E Ratio Valuation 30.6x 50.6x Lower Multiple NVS
Forward P/E Ratio Valuation 16.2x 18.2x Lower Multiple NVS
Revenue Growth (YoY) Growth +4.7% +10.3% Higher Growth ABBV
Operating Margin (TTM) Profitability 34.0% 36.6% Higher Margin ABBV
Net Profit Margin Profitability 17.5% 15.7% Higher Margin NVS
Return on Equity (ROE) Capital Efficiency 24.3% 62.3% Higher ROE ABBV
52-Week Range Position Momentum 81% ($123โ€“$170) 94% ($191โ€“$303) Stronger Trend ABBV
Beta / 30D Volatility Risk Regime 0.31ฮฒ ยท 27% Vol -0.03ฮฒ ยท 20% Vol Lower Realized Risk ABBV
Unified Institutional Score Composite Signal 41.5 / 100 (SELL) 54.0 / 100 (HOLD) Higher Composite ABBV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVS vs ABBV Buy Guide
NVS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live NVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABBV BREAKOUT
94d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live ABBV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVS nor ABBV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.